Group 1 - The company expects a revenue growth of approximately 110% to 120% for the fiscal year ending December 31, 2025, compared to the fiscal year ending December 31, 2024, primarily due to significant progress in the commercialization of its core product, the TUMAI® laparoscopic surgical robot [1] - The company has signed over 100 new orders in overseas markets, with overseas sales revenue exceeding five times that of the previous year, indicating strong global expansion momentum [1] - As of the date of the announcement, the total commercial orders for TUMAI globally exceeded 180 units, with the cumulative installed base surpassing 120 units [1] Group 2 - The company anticipates an adjusted net loss of no more than RMB 240 million for the fiscal year ending December 31, 2025, which represents a reduction of over 50% compared to the adjusted net loss of approximately RMB 482 million for the fiscal year ending December 31, 2024 [1] - The reduction in loss is attributed to rapid revenue growth and significant decreases in product costs and operating expenses due to various cost control measures [1] - The company expects a substantial narrowing of free cash flow net outflow by over 80% for the fiscal year ending December 31, 2025, to no more than RMB 70 million [2]

2026 年 1 月 21 日 行业研究 价格立项指南出台，关注国产手术机器人商业化推进 ——手术机器人行业跟踪报告 要点 事件：国家医保局近日正式印发《手术与治疗辅助操作类医疗服务价格项目立 项指南（试行）》（以下简称《立项指南》），围绕 3D 打印、示踪增强成像、 能量器械、术中影像引导、机械臂与远程手术等医疗科技创新成果，进行统一 价格立项，规范形成 37 项价格项目、5 项加收项、1 项扩展项。 点评： 国产商业化加速推进，进口替代确定性强。国内手术机器人行业起步较晚，市 场长期由外资品牌主导。随着《立项指南》的发布、叠加"大规模设备更新" 政策红利延续、国产设备性价比优势凸显，我们认为手术机器人行业渗透率将 加速提升；本土设备在二三线医院及基层市场的教育成效显著，国产替代确定 性强。以腔镜手术机器人为例，随着国产龙头企业产能释放及临床数据验证成 熟，达芬奇的垄断格局正在被逐步重塑。据 RoboticTech 统计，2025 年腔镜 手术机器人中标量方面，国产品牌首次实现对进口品牌的反超，达芬奇的市场 份额进一步被压缩，微创、精锋、思哲睿、术锐等国产品牌中标量持续攀升， 市场格局从"单极垄断"迈向"多 ...

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Insights - The report highlights the implementation of the "Guidelines for Project Approval of Surgical and Treatment Auxiliary Operations (Trial)" by the National Medical Insurance Administration, which aims to standardize pricing for medical technology innovations, including surgical robots [4][5] - The guidelines establish a pricing management framework for surgical robots, potentially leading to a significant transformation in the industry by promoting the use of advanced surgical technologies in complex procedures [5] - The report identifies key beneficiaries in the surgical robot market, including Tianzhihang, which holds over 40% market share in China's orthopedic surgical robot market, and MicroPort Robotics, which is expanding its global presence [6] Summary by Relevant Sections Industry Overview - The closing index for the industry is 8541.18, with a 52-week high of 9323.49 and a low of 6876.88 [2] Beneficiary Companies - Tianzhihang is expected to optimize its business model following the new policy, with a projected increase in surgical robot usage and related consumables and service revenue [6] - MicroPort Robotics has seen a significant increase in global orders for its core product, the Tumi laparoscopic surgical robot, indicating a strong market validation of its globalization strategy [6] - Other notable companies mentioned include Precision Medical-B, United Imaging, and Sanyou Medical [6]

Core Insights - The National Healthcare Security Administration (NHSA) has released the "Guidelines for Auxiliary Operation Project Establishment," establishing a unified pricing management framework for surgical robots and precision medical technologies, marking a significant commercial turning point for the industry [1][2] Group 1: Event Overview - The "Guidelines for Auxiliary Operation Project Establishment" will officially take effect on January 20, 2026, focusing on medical technology innovations such as 3D printing, imaging enhancement, energy devices, intraoperative imaging guidance, robotic arms, and remote surgery [1] - The guidelines standardize 37 pricing items, 5 additional charges, and 1 expansion item, aiming to lead the upgrade of medical technologies and transition from traditional treatment to precision medicine [1] Group 2: Industry Impact - The guidelines create a pricing framework for robotic surgeries and remote surgeries, which is expected to drive the industry from quantitative to qualitative development [2] - The pricing model is tiered based on the level of participation and clinical value of surgical robots, encouraging medical institutions to prioritize robotic applications in complex surgeries [2] Group 3: Beneficiary Companies - Tianzhihang is projected to maintain over 40% market share in the domestic orthopedic surgical robot market by 2025, with a significant number of successful bids and a dominant position in the market [3] - The company is expected to optimize its business model further, with rapid increases in surgical volumes leading to growth in consumables and service revenues [3] - MicroPort Robotics is experiencing validation of its globalization strategy, with a significant increase in commercial orders for its core product, the Tumi laparoscopic surgical robot, and is expected to maintain its competitive edge in the domestic market [3]

Core Viewpoint - The successful IPO of Precision Medical marks a significant milestone for the company and the domestic high-end medical equipment industry, transitioning from a phase of "following" to "leading" in the surgical robot sector [1][15]. Group 1: Market Response and Performance - Precision Medical's IPO was met with overwhelming demand, achieving a subscription rate of 1,091.94 times during the public offering and 25.18 times in the international placement, with the stock price surging by 39.11% on its debut [1]. - The company's stock continued to rise, reaching HKD 55.7 per share shortly after listing, reflecting strong investor confidence in its growth prospects [1]. Group 2: Industry Landscape - The domestic surgical robot industry is at a pivotal point, shifting focus from obtaining regulatory approvals to scaling production and integrating products into hospital workflows [3]. - The Chinese surgical robot market is projected to reach CNY 102.019 billion by 2033, with a compound annual growth rate (CAGR) of 34.3% from 2024 to 2033 [3]. Group 3: Company Strategy and Innovation - Precision Medical has established a comprehensive business model that integrates product development, market strategy, and clinical ecosystem, creating a "flywheel" effect that drives growth [6][7]. - The company is the first in China to commercialize multi-port, single-port, and natural orifice surgical robots, offering a versatile product matrix that addresses various surgical needs [7]. Group 4: Financial Performance - Precision Medical reported a revenue of CNY 160 million for 2024, a significant increase of 233% year-on-year, with the first half of 2025 nearing CNY 149 million, reflecting a nearly 400% growth compared to the same period last year [8]. - The company maintains a gross margin above 60%, with a gross profit of approximately CNY 93.85 million in the first half of 2025, indicating strong market competitiveness and pricing power [8]. Group 5: Clinical Ecosystem and Long-term Strategy - The company emphasizes the importance of post-sale services, including training and clinical support, to build a robust clinical ecosystem that enhances customer loyalty and creates a sustainable competitive advantage [9]. - Precision Medical aims to evolve from a device manufacturer to an "intelligent surgical solution platform," expanding its offerings to include pre-operative planning, specialized high-end consumables, and post-operative data analysis services [13].

Core Viewpoint - MicroPort Scientific Corporation (微创机器人-B) has seen a significant increase in its stock price, rising over 4% and currently trading at 27.66 HKD with a transaction volume of 159 million HKD, following the announcement of a substantial increase in order volume for its core products [1] Group 1: Order Volume and Product Performance - The company reported that its cumulative order volume for core products, including endoscopic, orthopedic, and vascular intervention devices, has surpassed 230 units [1] - The TiMAY endoscopic surgical robot has achieved over 160 commercial orders globally, with nearly 120 new orders received this year [1] - By 2025, TiMAY is projected to rank among the top two in global order volume according to public statistics [1] Group 2: Market Penetration - In the domestic market, TiMAY has made significant progress in both leading public hospitals and high-end private hospitals, with 23% of installed hospitals being top-tier hospitals and over 90% being tertiary hospitals [1] - The company has established a high-quality installation pattern driven by clinical value and professional capability accumulation [1] Group 3: International Expansion - TiMAY's overseas market presence has expanded to over 40 countries and regions across Asia, Europe, Africa, Oceania, and South America, gaining recognition from local top institutions [1] - The product has achieved "multiple sales and installations in multiple hospitals" in 15 countries, indicating a normalized, networked, and scaled usage within mature healthcare systems globally [1]

Core Viewpoint - The article highlights the successful commercialization and global expansion of the TUMAI® robotic surgical system, marking a significant milestone in China's medical technology innovation and its role in global healthcare [2][4]. Group 1: Commercialization Milestones - The TUMAI® robotic surgical system has officially landed in Brazil at Hospital Unimed Foz do Iguaçu, marking the 100th commercial installation globally, with over 160 cumulative orders to date [2][10]. - The rapid growth in orders from October to December 2025, from over 100 to 160+, showcases the unprecedented commercialization speed of the TUMAI® system [10]. - The TUMAI® robot has achieved a significant market presence, becoming the first domestic laparoscopic surgical robot to reach 100 commercial installations, indicating its reliability and clinical stability [2][10]. Group 2: Strategic Partnerships and Market Integration - Hospital Unimed Foz do Iguaçu represents a key part of Brazil's Unimed healthcare system, the largest cooperative healthcare system in Brazil, indicating TUMAI®'s deep integration capabilities within established healthcare frameworks [8]. - The successful installation at this flagship hospital demonstrates TUMAI®'s ability to align with procurement models, maintenance costs, and training systems, enhancing its market expansion potential in Brazil and Latin America [8][10]. - The TUMAI® robot's entry into various international markets, including partnerships with top medical institutions in countries like Belgium, Italy, and India, reflects its growing global footprint and acceptance [25][29]. Group 3: Ecosystem Development and Technological Advancements - A multi-layered robotic surgical ecosystem is forming, integrating top experts, regional medical centers, and grassroots hospitals, facilitating the widespread adoption of robotic surgery [32]. - The TUMAI® system has enabled remote surgical capabilities across various regions, including successful cross-border surgeries in the Middle East and Europe, enhancing the accessibility of high-quality surgical resources [34][41]. - The article emphasizes the importance of TUMAI®'s technological advancements and its ability to adapt to diverse regulatory and clinical environments, establishing a competitive edge in the global market [42].

Core Insights - The company, MicroPort Scientific Corporation, reported that its cumulative order volume for core products in the fields of endoscopy, orthopedics, and vascular intervention has exceeded 230 units [1] - The Tumi endoscopic surgical robot has achieved over 160 commercial orders globally, with nearly 120 new orders acquired this year, positioning it among the top two in global order volume for 2025 [1] - The company has completed over 150 commercial installations of its products, with Tumi surpassing 100 installations, all of which have received signed acceptance reports from users [1] Product Performance - Tumi is the first domestically produced endoscopic surgical robot to achieve over 100 commercial installations, demonstrating its reliability and clinical stability at an industry infrastructure level [1] - The advancements in Tumi's quality compliance, production processes, engineering validation, system delivery, clinical adaptation, and overall process assurance capabilities signify a comprehensive leap in its operational standards [1]

Core Viewpoint - MicroPort Robotics-B (02252) has seen a significant increase in its stock price, with a rise of over 5% in early trading, reflecting strong market confidence following the announcement of robust order volumes for its core products [1] Group 1: Company Performance - The cumulative order volume for MicroPort Robotics' core products, including endoscopic, orthopedic, and vascular intervention devices, has surpassed 170 units [1] - The "TUMAI" endoscopic surgical robot has achieved over 100 commercial orders globally, with nearly 80 units installed, maintaining the leading position among domestic brands [1] - The company is entering a phase of accelerated commercialization, indicating strong growth potential in the market [1] Group 2: Market Analysis - JPMorgan has reported that the global order momentum for MicroPort Robotics remains strong, leading to an upward revision of the installation forecast for the year from 84 units to 105 units [1] - This adjustment is primarily driven by growth in overseas markets and the assumption that orders can be converted to sales within less than a quarter [1] - The expected improvement in installation volume and product mix is anticipated to enhance the gross margin by 1 to 1.5 percentage points [1] Group 3: Investment Outlook - Morgan Stanley has raised its target price for MicroPort Robotics from HKD 30.9 to HKD 42, maintaining an "Overweight" rating on the stock [1]

Core Viewpoint - MicroPort Scientific Corporation's stock (02252) has seen a rise of over 5%, reaching HKD 30.2, with a trading volume of HKD 130 million, following the announcement of significant order growth for its core products [1] Group 1: Order Volume and Product Performance - As of the announcement date, the cumulative order volume for the company's core products, including laparoscopic, orthopedic, and vascular intervention devices, has exceeded 170 units [1] - The TiMAY laparoscopic surgical robot has achieved over 100 commercial orders globally, with nearly 80 units installed, making it the leading domestic brand in this sector [1] Group 2: International Market Expansion - The TiMAY robot has surpassed 60 overseas orders, with installations across nearly 40 countries and regions, including Asia, Europe, Africa, Oceania, and South America [1] - The company has successfully conducted large-scale clinical surgeries in mainstream hospital systems in countries such as Italy, Belgium, India, Brazil, Argentina, and the UAE [1] Group 3: Milestone Achievements - The company has reached a significant milestone in its global high-end medical market strategy, with the TiMAY robot being commercially deployed in a top-tier medical institution ranked among the world's top two [1] - The successful implementation of a comprehensive intelligent surgical solution has been achieved through both single-port and multi-port series deployments [1]